Related Experiment Videos
Comparative efficacy of DMP 840 against mouse and human solid tumor models
1Division of Hematology/Oncology, Wayne State University, Detroit, MI 48201, USA.
Investigational New Drugs
|January 1, 1995
Summary
DMP 840, a bis-naphthalimide antitumor agent, showed selective in vivo activity against human tumors but not mouse tumors. Ongoing Phase II trials will determine its clinical efficacy in patients.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- DMP 840 is a bis-naphthalimide antitumor agent that has completed Phase I and is in Phase II clinical trials.
- Preclinical studies demonstrated curative activity against various human tumor xenograft models.
Purpose of the Study:
- To evaluate the in vitro and in vivo antiproliferative activity of DMP 840.
- Focus on predominantly mouse tumor models for in vivo testing.
Main Methods:
- In vitro assessment using disk diffusion soft agar colony formation assay against mouse and human tumor cell lines.
- In vivo testing utilized comparable selective mouse solid tumors.
Main Results:
- In vitro, DMP 840 showed equal cytotoxicity against human tumors, mouse tumors, and normal cells.
- In vivo, DMP 840 exhibited modest or no activity against most mouse tumors, with activity only at toxic doses.
- Notably, DMP 840 was highly active against human breast tumor MX-1 xenografts in both athymic nude and SCID mice.
Conclusions:
- No selective in vitro cytotoxicity was observed for human versus mouse tumor cell lines.
- Selective in vivo antitumor activity was noted for human xenograft tumors, distinguishing it from mouse tumor responses.
- The compound's differential in vivo activity between human and mouse tumors is unique and warrants further investigation in ongoing clinical trials.